查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423590

到 2030 年基層醫療POC 診斷市場預測：按產品類型、技術、樣本類型、分銷管道、最終用戶和地區進行的全球分析

Primary Care POC Diagnostics Market Forecasts to 2030 - Global Analysis By Product (Urinalysis, Ambulatory Chemistry, Infectious Diseases Testing Kits and Other Products), Technology, Sample Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球基層醫療POC 診斷市場規模為 167 億美元，預計在預測期內複合年成長率為 8.5%，到 2030 年將達到 295 億美元。

基層醫療職業點 (POC) 診斷是基層醫療環境中使用的診斷工具和測試，使醫療保健專業人員能夠立即獲得靠近患者的測試結果。這些測試在患者的照護端或附近進行，可以快速輕鬆地存取診斷資料，以便快速做出臨床決策。在患者就診期間，這些測試可以提供快速資料（通常在幾分鐘內），使負責人能夠快速做出臨床決策。在基層醫療機構中維持高品質的測試和可靠的觀察需要 POC 診斷，以確保準確性、可靠性並符合監管標準。

據世界衛生組織 (WHO) 稱，全球約有 3.54 億人乙型肝炎或丙型肝炎呈陽性，但仍未被診斷和治療。世界衛生組織的目標是到2030年新增感染病例減少90%，死亡人數減少65%。

醫療保健環境中對 POC 解決方案的需求

對 POC 解決方案的需求推動了患者照護端快速檢測的可用性。這使得在基層醫療中遇到患者時能夠快速訪問診斷資訊，從而實現快速臨床選擇和及時治療。這種診斷方法無需將樣本運送到中央測試設施，從而顯著加快了測試結果的速度。快速存取此類資訊可以促進基層醫療機構更有效的工作流程，並加快患者治療速度，尤其是在緊急情況下。

較低的醫療費用和財務限制所帶來的價格壓力

報銷和使用點 (POC) 診斷測試報銷的減少可能會導致患者和醫療機構的成本增加。因此，某些測試的成本和可用性可能會降低，特別是在小型基層醫療機構和弱勢社區。此外，財務限制迫使醫療機構選擇更便宜、品質較低的現場護理 (POC) 診斷測試，從而損害了測試覆蓋範圍、準確性和可靠性，阻礙了市場成長。

即時診斷結果的需求

速效結果的主要目的是加速基層醫療機構的臨床決策。照護端 (POC) 診斷使醫療保健專業人員能夠在單次就診中快速、明智地決定如何最好地治療患者。這些診斷無需中心實驗室，從而大大縮短了檢測結果的時間。這種資訊的快速可用性確保了及時干預並加快了診斷過程。

缺乏準確性和可靠性

基層醫療POC 診斷測試的不準確或不可靠的結果可能導致誤診、無效治療和延誤必要的治療。這可能會對健康結果產生不利影響並威脅患者安全。當醫療保健專業人員和機構使用有錯誤記錄的基層醫療POC 診斷測試時，患者可能會對測試不滿意或失去信心。患者對醫療照護的信任和滿意度可能會受到影響。

COVID-19 的影響

快速、輕鬆地進行 SARS-CoV-2 檢測的需求導致了對快速照護端診斷的需求激增。在基層醫療機構中，分子 POC 檢測和側流檢測 (LFA) 等技術已成為快速識別 COVID-19 的關鍵。此外，遠端醫療服務和遠距測試選項已變得普遍，以試圖減少接觸並保持社會隔離。因此，一些 POC 測試已適用於遠端醫療，允許患者在遠端醫療提供者的監督下在家中進行測試。

預計門診化學將成為預測期內最大的領域

門診化學領域預計將出現良好的成長。術語「門診化學」描述了在傳統實驗室環境之外進行的生化分析或化學測試，通常是在照護端 (POC) 或門診治療環境中進行。其主要目的是快速且準確地收集基本生物化學檢驗觀察，以便在門診和基層醫療遇到患者時快速做出臨床決策。當在門診進行生物化學檢驗時，患者可以前往不太集中的設施進行常規檢測，這可能會節省時間並促進診斷。

側向流動試驗法（LFA）產業預計在預測期內複合年成長率最高

側向流動試驗法（LFA）領域預計在預測期內複合年成長率最高。這些測試旨在確定生物樣本（例如血液、尿液、唾液或其他體液）中是否存在特定分析物。這些測試適用於基層醫療和照護端 (POC) 環境，在這些環境中，快速觀察對於及時進行臨床選擇、推動市場成長至關重要。

佔比最大的地區：

預計北美在預測期內將佔據最大的市場佔有率，因為美國大量基層醫療機構使用 POC 設備，並且該區域市場的很大一部分預計將佔據初級設置的最大市場佔有率。它還與提供產品和服務的大公司的存在有關。醫療保險和醫療補助服務中心敦促醫療保健提供者發起病人參與舉措。這以及學術機構為醫療保健研究和開發提供的資金籌措正在推動該地區的市場成長。

複合年成長率最高的地區：

亞太地區預計在預測期內將經歷最高的複合年成長率，因為該地區比其他亞太地區相對更加發達，擁有大量尖端和創造性的 POC 診斷解決方案。另一個關鍵促進因素是初級家庭醫療保健和支持性護理環境對這些解決方案的需求不斷成長。這是因為越來越多的公司正在開發該領域未實現的潛力。此外，由於公眾越來越意識到需要早期診斷疾病以提高患者存活率，預計亞太市場將會發展。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球基層醫療POC 診斷市場：依產品

  • 尿液檢查
  • 門診化學
  • 傳染病檢查套件
  • 血脂測試
  • 血糖值監測裝置
  • 血液學檢測設備
  • 血氣/電解質
  • Hb1Ac 測試
  • 自體免疫疾病
  • 凝血監測裝置
  • 心臟標記
  • 甲狀腺刺激素裝置
  • 藥物濫用測試
  • 懷孕和生育測試產品
  • 其他產品

第6章全球基層醫療POC 診斷市場：依技術分類

  • 免疫學測試
  • 側向流動試驗法（LFA）
  • 分子診斷
  • 臨床化學
  • 電化學和生物感測器技術
  • 其他技術

第7章全球基層醫療POC 診斷市場：依樣本類型

  • 尿
  • 血
  • 鼻和口咽拭子
  • 其他樣品類型

第8章全球基層醫療POC 診斷市場：按分銷管道

  • 藥局
  • 零售診所
  • 電子通訊平台
  • 其他分銷管道

第9章全球基層醫療POC 診斷市場：依最終用戶分類

  • 居家照護和自我測試
  • 醫院
  • 重症監護中心及重症監護中心
  • 門診護理設施
  • 臨床實驗室

第10章全球基層醫療POC診斷市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • BD Biosciences
  • Roche Diagnostics
  • Abbott Laboratories
  • bioMerieux
  • Instrumentation Laboratory
  • Quidel Corporation
  • Danaher Corporation
  • Siemens Healthcare
  • Agilent Technologies
  • Decode Genetics
  • Axis-Shield
  • Becton Dickinson
  • Nova Biomedical
  • Trividia Health, Inc.
  • OraSure Technologies, Inc.
  • Abaxis
Product Code: SMRC24824

According to Stratistics MRC, the Global Primary Care POC Diagnostics Market is accounted for $16.7 billion in 2023 and is expected to reach $29.5 billion by 2030 growing at a CAGR of 8.5% during the forecast period. Primary Care Point-of-Care (POC) Diagnostics are diagnostic tools and tests used in primary care settings that enable medical professionals to get test results right away in close proximity to the patient. These tests are carried out at the point of patient care, or in close proximity to it, providing quick and easy access to diagnostic data for prompt clinical decision-making. During patient consultations, these tests enable healthcare practitioners to make prompt clinical judgments since they yield data quickly often in a matter of minutes. Maintaining high-quality testing and dependable findings in primary care settings requires POC diagnostics to ensure accuracy, dependability, and compliance with regulatory criteria.

According to the World Health Organization (WHO), approximately 354 million people globally are hepatitis B or C positive, and diagnosis and treatment are unavailable. The WHO aims to control and reduce new infections by 90% and deaths by 65% by 2030.

Market Dynamics:

Driver:

Demand for point-of-care solutions in healthcare settings

The availability of rapid testing at the point of patient care is encouraged by the need for point-of-care solutions. This allows for quick clinical choices and timely treatments during patient consultations in primary care by providing quick access to diagnostic information. This diagnostics speeds up test results considerably by removing the requirement to ship samples to centralized laboratories. This quick access to information facilitates more effective workflows in primary care settings and speeds up patient care, especially for urgent situations which further enhance the growth of the market.

Restraint:

Price pressure as a result of reduced reimbursement and financial limitations

Lower reimbursements or reimbursement for point-of-care (POC) diagnostic tests may result in higher expenses for patients or healthcare institutions. This may result in a decrease in the cost or availability of certain tests, particularly for smaller primary care clinics or underprivileged communities. Additionally, financial restrictions may force healthcare institutions to choose less expensive, lower-quality point-of-care (POC) diagnostic tests, which might compromise test range, accuracy, or reliability with stunt in the growth of the market.

Opportunity:

Demand for immediate diagnostic results

Immediate outcomes' main objective is to speed up clinical decision-making in primary care settings. Point-of-care (POC) diagnostics allow medical professionals to quickly and intelligently decide how best to treat patients at a single visit. These diagnostics drastically shorten the time it takes to get test results by doing away with the requirement for centralized laboratories. Thus, quick information availability guarantees quick interventions and speeds up the diagnostic procedure creating wide range of opportunities for the market.

Threat:

Lack of accuracy and reliability

Results from primary care point-of-care diagnostic tests that are inaccurate or untrustworthy may result in misdiagnoses, ineffective therapies, or a delay in essential actions. This might have a detrimental effect on health outcomes and jeopardize patient safety. When primary care POC diagnostic tests with a track record of errors are used by healthcare practitioners or institutions, patients may become dissatisfied or lose faith in them. Patient trust in their medical care and satisfaction may be impacted by this.

Covid-19 Impact

Demand for rapid point-of-care (POC) diagnostics surged in response to the need for quick and easily accessible SARS-CoV-2 testing. In primary care settings, procedures such molecular POC testing and lateral flow assays (LFAs) have become indispensable for rapid COVID-19 identification. Moreover, telehealth services and remote testing choices proliferated in an attempt to reduce exposure and preserve social isolation. Thus a few POC tests were modified for use in telemedicine so that patients may take tests at home under the supervision of a remote provider.

The ambulatory chemistry segment is expected to be the largest during the forecast period

The ambulatory chemistry segment is estimated to have a lucrative growth, as the term "ambulatory chemistry" describes the practice of doing biochemical analyses or chemistry tests outside of a conventional laboratory environment, usually at point-of-care (POC) or ambulatory care settings. The principal objective is to expedite and accurately collect basic biochemistry test findings to facilitate prompt clinical decision-making during patient consultations in ambulatory or primary care settings. When biochemical tests are performed in ambulatory settings, patients can visit less centralized facilities for routine testing, which can save time and facilitate diagnosis.

The lateral flow assays (LFAs) segment is expected to have the highest CAGR during the forecast period

The lateral flow assays (LFAs) segment is anticipated to witness the highest CAGR growth during the forecast period, because these tests are easy to use, quick to complete, and reasonably priced. They are intended to find out whether a certain analyze is present in biological samples like blood, urine, saliva, or other body fluids. These tests are appropriate for use in primary care or point-of-care (POC) settings where prompt findings are essential for making timely clinical choices thus encourage the growth of the market.

Region with largest share:

North America is projected to hold the largest market share during the forecast period because so many primary care facilities in the United States use POC equipment and the significant portion of this regional market has also been linked to the existence of significant firms in the nation providing goods and services for primary settings. Healthcare providers are being urged by the Centers for Medicare & Medicaid Services to start patient engagement initiatives. The market is being driven by this as well as the availability of financing for healthcare R&D by academic institutions boost the growth of the market in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the availability of several cutting-edge and creative POC diagnostic solutions, the Asia-Pacific market is comparatively more developed than the rest of the globe. Another important growth driver is the increasing demand for these solutions in primary home healthcare and supported healthcare settings. This is explained by the fact that more businesses are taking use of the unrealized potential in the area. Furthermore, it is anticipated that the Asia Pacific market would develop as a result of rising public awareness of the need of early illness diagnosis to increase patient survival rates.

Key players in the market

Some of the key players profiled in the Primary Care POC Diagnostics Market include BD Biosciences, Roche Diagnostics, Abbott Laboratories, bioMerieux, Instrumentation Laboratory, Quidel Corporation, Danaher Corporation, Siemens Healthcare, Agilent Technologies, Decode Genetics, Axis-Shield, Becton Dickinson, Nova Biomedical, Trividia Health, Inc., OraSure Technologies, Inc. and Abaxis

Key Developments:

In November 2023, BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

In November 2023, BD a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a memorandum of understanding (MOU) for a joint effort to combat tuberculosis (TB)

In September 2023, bbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Products Covered:

  • Urinalysis
  • Ambulatory Chemistry
  • Infectious Diseases Testing Kits
  • Lipid Testing
  • Glucose Monitoring Devices
  • Hematology Testing Devices
  • Blood Gas/Electrolytes
  • Hb1Ac Testing
  • Autoimmune Disease
  • Coagulation Monitoring Devices
  • Cardiac Markers
  • Thyroid Stimulating Hormone Devices
  • Drug Abuse Testing
  • Pregnancy & Fertility Testing Products
  • Other Products

Technologies Covered:

  • Immunoassays
  • Lateral Flow Assays (LFAs)
  • Molecular Diagnostics
  • Clinical Chemistry
  • Electrochemical & Biosensor Technologies
  • Other Technologies

Sample Types Covered:

  • Urine
  • Blood
  • Nasal & Oropharyngeal Swabs
  • Other Sample Types

Distribution Channels Covered:

  • Pharmacies
  • Retail clinics
  • E-comm. Platforms
  • Other Distribution Channels

End Users Covered:

  • Home Care & Self Testing
  • Hospitals
  • Critical Care Centers & Urgent care centers
  • Ambulatory Care Facilities
  • Clinical Laboratories

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Primary Care POC Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Urinalysis
  • 5.3 Ambulatory Chemistry
  • 5.4 Infectious Diseases Testing Kits
  • 5.5 Lipid Testing
  • 5.6 Glucose Monitoring Devices
  • 5.7 Hematology Testing Devices
  • 5.8 Blood Gas/Electrolytes
  • 5.9 Hb1Ac Testing
  • 5.10 Autoimmune Disease
  • 5.11 Coagulation Monitoring Devices
  • 5.12 Cardiac Markers
  • 5.13 Thyroid Stimulating Hormone Devices
  • 5.14 Drug Abuse Testing
  • 5.15 Pregnancy & Fertility Testing Products
  • 5.16 Other Products

6 Global Primary Care POC Diagnostics Market, By Technology

  • 6.1 Introduction
  • 6.2 Immunoassays
  • 6.3 Lateral Flow Assays (LFAs)
  • 6.4 Molecular Diagnostics
  • 6.5 Clinical Chemistry
  • 6.6 Electrochemical & Biosensor Technologies
  • 6.7 Other Technologies

7 Global Primary Care POC Diagnostics Market, By Sample Type

  • 7.1 Introduction
  • 7.2 Urine
  • 7.3 Blood
  • 7.4 Nasal & Oropharyngeal Swabs
  • 7.5 Other Sample Types

8 Global Primary Care POC Diagnostics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Pharmacies
  • 8.3 Retail clinics
  • 8.4 E-comm. Platforms
  • 8.5 Other Distribution Channels

9 Global Primary Care POC Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Home Care & Self Testing
  • 9.3 Hospitals
  • 9.4 Critical Care Centers & Urgent care centers
  • 9.5 Ambulatory Care Facilities
  • 9.6 Clinical Laboratories

10 Global Primary Care POC Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 BD Biosciences
  • 12.2 Roche Diagnostics
  • 12.3 Abbott Laboratories
  • 12.4 bioMerieux
  • 12.5 Instrumentation Laboratory
  • 12.6 Quidel Corporation
  • 12.7 Danaher Corporation
  • 12.8 Siemens Healthcare
  • 12.9 Agilent Technologies
  • 12.10 Decode Genetics
  • 12.11 Axis-Shield
  • 12.12 Becton Dickinson
  • 12.13 Nova Biomedical
  • 12.14 Trividia Health, Inc.
  • 12.15 OraSure Technologies, Inc.
  • 12.16 Abaxis

List of Tables

  • Table 1 Global Primary Care POC Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Primary Care POC Diagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Primary Care POC Diagnostics Market Outlook, By Urinalysis (2021-2030) ($MN)
  • Table 4 Global Primary Care POC Diagnostics Market Outlook, By Ambulatory Chemistry (2021-2030) ($MN)
  • Table 5 Global Primary Care POC Diagnostics Market Outlook, By Infectious Diseases Testing Kits (2021-2030) ($MN)
  • Table 6 Global Primary Care POC Diagnostics Market Outlook, By Lipid Testing (2021-2030) ($MN)
  • Table 7 Global Primary Care POC Diagnostics Market Outlook, By Glucose Monitoring Devices (2021-2030) ($MN)
  • Table 8 Global Primary Care POC Diagnostics Market Outlook, By Hematology Testing Devices (2021-2030) ($MN)
  • Table 9 Global Primary Care POC Diagnostics Market Outlook, By Blood Gas/Electrolytes (2021-2030) ($MN)
  • Table 10 Global Primary Care POC Diagnostics Market Outlook, By Hb1Ac Testing (2021-2030) ($MN)
  • Table 11 Global Primary Care POC Diagnostics Market Outlook, By Autoimmune Disease (2021-2030) ($MN)
  • Table 12 Global Primary Care POC Diagnostics Market Outlook, By Coagulation Monitoring Devices (2021-2030) ($MN)
  • Table 13 Global Primary Care POC Diagnostics Market Outlook, By Cardiac Markers (2021-2030) ($MN)
  • Table 14 Global Primary Care POC Diagnostics Market Outlook, By Thyroid Stimulating Hormone Devices (2021-2030) ($MN)
  • Table 15 Global Primary Care POC Diagnostics Market Outlook, By Drug Abuse Testing (2021-2030) ($MN)
  • Table 16 Global Primary Care POC Diagnostics Market Outlook, By Pregnancy & Fertility Testing Products (2021-2030) ($MN)
  • Table 17 Global Primary Care POC Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 18 Global Primary Care POC Diagnostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 19 Global Primary Care POC Diagnostics Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 20 Global Primary Care POC Diagnostics Market Outlook, By Lateral Flow Assays (LFAs) (2021-2030) ($MN)
  • Table 21 Global Primary Care POC Diagnostics Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 22 Global Primary Care POC Diagnostics Market Outlook, By Clinical Chemistry (2021-2030) ($MN)
  • Table 23 Global Primary Care POC Diagnostics Market Outlook, By Electrochemical & Biosensor Technologies (2021-2030) ($MN)
  • Table 24 Global Primary Care POC Diagnostics Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 25 Global Primary Care POC Diagnostics Market Outlook, By Sample Type (2021-2030) ($MN)
  • Table 26 Global Primary Care POC Diagnostics Market Outlook, By Urine (2021-2030) ($MN)
  • Table 27 Global Primary Care POC Diagnostics Market Outlook, By Blood (2021-2030) ($MN)
  • Table 28 Global Primary Care POC Diagnostics Market Outlook, By Nasal & Oropharyngeal Swabs (2021-2030) ($MN)
  • Table 29 Global Primary Care POC Diagnostics Market Outlook, By Other Sample Types (2021-2030) ($MN)
  • Table 30 Global Primary Care POC Diagnostics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Primary Care POC Diagnostics Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 32 Global Primary Care POC Diagnostics Market Outlook, By Retail clinics (2021-2030) ($MN)
  • Table 33 Global Primary Care POC Diagnostics Market Outlook, By E-comm. Platforms (2021-2030) ($MN)
  • Table 34 Global Primary Care POC Diagnostics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 35 Global Primary Care POC Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 36 Global Primary Care POC Diagnostics Market Outlook, By Home Care & Self Testing (2021-2030) ($MN)
  • Table 37 Global Primary Care POC Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 Global Primary Care POC Diagnostics Market Outlook, By Critical Care Centers & Urgent care centers (2021-2030) ($MN)
  • Table 39 Global Primary Care POC Diagnostics Market Outlook, By Ambulatory Care Facilities (2021-2030) ($MN)
  • Table 40 Global Primary Care POC Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.